Stock Performance - CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20, driven by higher trading volume compared to a typical session [1] - The stock has gained 1.4% over the past four weeks [1] - Tarsus Pharmaceuticals, Inc. (TARS) finished the last trading session 2.9% higher at $48.11, but has returned -13.5% over the past month [3] Financial Expectations - CRISPR Therapeutics is expected to post a quarterly loss of $1.20 per share, representing a year-over-year change of -209.1% [2] - Revenues are expected to be $10.83 million, down 94.6% from the year-ago quarter [2] - The consensus EPS estimate for CRISPR Therapeutics has remained unchanged over the last 30 days [3] - Tarsus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.70, representing a year-over-year change of +46.6% [4] Strategic Priorities - CRISPR Therapeutics outlined key strategic priorities related to the ongoing launch of Casgevy and certain pipeline goals for 2025, which may have driven the recent share price rally [1] Industry and Rankings - CRISPR Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry [3] - The stock currently carries a Zacks Rank 3 (Hold) [3] - Tarsus Pharmaceuticals currently boasts a Zacks Rank of 2 (Buy) [4]

Shares of CRISPR Therapeutics (CRSP) have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood disorders, much of these gains have pared mainly due to the waning interest of investors in CRSP.Despite securing the first product approval in Casgevy, the company is yet to record revenues from its sales. Also, a lack of pipeline updates beyond Casgevy’s approval is not sitting well with the investors.Anot ...

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

Key Points Company and Industry Overview 1. **Company Name and Stock Symbol**: CRISPR Therapeutics AG (NASDAQ: CRSP) [2] 2. **Industry**: Biotechnology, specifically gene editing and gene therapy [3] 3. **Business Segments**: Hemoglobinopathies (heme), oncology, autoimmune, cardiovascular medicines, and rare diseases [3] Pipeline and Products 4. **Clinical Programs**: Five programs in various disease areas, including oncology, autoimmune, cardiovascular, and rare diseases [3] 5. **Preclinical Programs**: Ten preclinical programs with promising potential [3] 6. **Approved Drug**: CASGEVY, a hemoglobinopathy treatment, partnered with Vertex [4] Financial and Business Performance 7. **Revenue**: Not specified in the provided text [3] 8. **Business Model**: Divided into four franchises, with hemoglobinopathies being the core [3] Future Outlook 9. **Outlook**: One of the most consequential years in the company's journey [5] 10. **Risk Factors**: Encourages participants to visit the company's website for a full risk list [6] Additional Information 11. **Conference**: 43rd Annual JPMorgan Healthcare Conference [2] 12. **Date**: January 14, 2025 [2] 13. **Time**: 5:15 PM ET [2] 14. **Participants**: Samartha Kulkarni (CEO and Chairman), Fanchen Zhou (JPMorgan) [2]

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics (CRSP -2.12%) could more than double your money in the year ahead.But before committing any amount of your own money to this stock, it's important to remember the analysts who recommended it have very little t ...

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic prior ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run.To be clear, it doesn't always work out that way, and there are risks with these types of stoc ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of ...

Background and Expertise - The analyst has a strong background in life sciences with a PhD in Bioengineering and over 20 years of experience in the research and development of novel Cell & Gene Therapies (CGT) [2] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [2] Disclosure and Independence - The analyst has no stock, option, or similar derivative positions in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The analyst is not receiving compensation for the article other than from Seeking Alpha and has no business relationship with any company whose stock is mentioned [1] - The analyst is associated with another Seeking Alpha contributor, "Euro Invest," but each works independently and adheres to Seeking Alpha's Shared Association Guidelines [2]

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan position ...